title: Monoclonal antibody successes in the clinic.
abstract: Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.
authors.affiliation: Tufts University Center for the Study of Drug Development (CSDD), 192 South Street, Suite 550, Boston, Massachusetts 02111, USA. janice.reichert@tufts.edu
authors.forename: Janice M
authors.initials: JM
authors.lastname: Reichert
authors.forename: Clark J
authors.initials: CJ
authors.lastname: Rosensweig
authors.forename: Laura B
authors.initials: LB
authors.lastname: Faden
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Dewitz
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D001709:Biotechnology / Q000379:methods / Q000639:trends; D002626:Chemistry, Pharmaceutical / Q000639:trends; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry / Q000639:trends; D006801:Humans; D006825:Hybridomas / Q000378:metabolism; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal